Skip to main content

Therapeutic Areas

Cell Therapy


Adoptive Cell Therapy

  • Chimeric antigen receptor (CAR) T-cell therapy - Adoptive cell therapies like CAR-T involve collection of immune cells from a patient followed by ex vivo manipulation and/or expansion and reinfusion, and are the foundations of immuno-oncology today after showing success in the treatment of hematologic malignancies (MSD, Luminex, PCR, Flow Cytometry, ELISpot)
  • Customized, specific assessment of hematologic malignancies.

Viracor Offerings:

  • Platforms for immunoassay ligand binding assays
  • Detection/quantification of gene expressions performed by qPCR.
  • Vector copy number (VCN)
  • ELISPOT analysis is for the measurement of specific T- or B cell responses.
  • Flow cytometry for analysis of cellular targets including T cell activation, and cytokine release syndrome (CRS)

Additional genomics capabilities for clinical immunotherapy studies:

  • Predictive biomarker assays (whole exome or RNA sequencing)
  • qPCR or microarray-based RNA expression assays
  • qPCR and ddPCR for replication-competent lentivirus (RCL) and replication-competent retrovirus (RCR) testing, and measuring gene persistence
  • Gene expression profiles for detecting and characterizing mutations/biomarkers in cancer cells
  • Comprehensive targeted NGS panels or tumor profiling assays to detect known and emerging biomarkers, and measure tumor mutational burden
Back to top